Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial

IMPORTANCE AND OBJECTIVE: The aim of this pragmatic, embedded, adaptive trial was to measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added to an evolving standard of care (SOC), for clinical management of inpatients with moderate to severe COVID-19 disease. DESIGN:...

Descripción completa

Detalles Bibliográficos
Autores principales: Branch-Elliman, Westyn, Ferguson, Ryan, Doros, Gheorghe, Woods, Patricia, Leatherman, Sarah, Strymish, Judith, Datta, Rupak, Goswami, Rekha, Jankowich, Matthew D., Shah, Nishant R., Taylor, Thomas H., Page, Sarah T., Schiller, Sara J., Shannon, Colleen, Hau, Cynthia, Flynn, Maura, Holmberg, Erika, Visnaw, Karen, Dhond, Rupali, Brophy, Mary, Monach, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880885/
https://www.ncbi.nlm.nih.gov/pubmed/35213547
http://dx.doi.org/10.1371/journal.pone.0263591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880885/
https://www.ncbi.nlm.nih.gov/pubmed/35213547
http://dx.doi.org/10.1371/journal.pone.0263591

Ejemplares similares